In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

It's important to consider your comfort with risk before diving in.

While the SpaceX IPO may be in the rearview mirror, its trading still dominated financial headlines this week. Read more here.

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Waltham biotech has beat out ...

CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...

The biotech IPO window looks like it’s reopening. This past week closed with three biotech companies joining the public markets, a flurry of activity that helped make April the biggest month for ...

Parabilis Medicines has raised $670M, topping Moderna's 2018 debut, to become the largest biotech listing on Nasdaq. $PBLS ...

This year’s crop of biotechnology IPOs features an unusual star in an industry better known for targeting severe diseases: Veradermics, whose shares have rocketed on the potential of its hair-loss ...